Sibrafiban (Genentech)

Feldstein, C.A.

Idrugs the Investigational Drugs Journal 2(5): 460-465

1999


ISSN/ISBN: 1369-7056
PMID: 16155849
Document Number: 511749
Sibrafiban (G-7453) is an orally active non-peptide GPIIb/IIIa antagonist, under development by Genentech and Hoffmann-La Roche, and in phase III trials as an antithrombotic. Roche intends to file for marketing approval in 1999. Merrill Lynch predicts a product launch in 2001.

Document emailed within 1 workday
Secure & encrypted payments